Burning Rock Biotech Ltd. ( (BNR) ) has released its Q2 earnings. Here is a breakdown of the information Burning Rock Biotech Ltd. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Burning Rock Biotech Limited, a company specializing in next-generation sequencing technology for precision oncology, has released its financial results for the second quarter of 2025. The company, which operates in the healthcare sector, focuses on late-stage cancer therapy selection and early cancer detection.
In the second quarter of 2025, Burning Rock reported a total revenue of RMB148.5 million, marking a 9.6% increase compared to the same period in 2024. This growth was primarily driven by a significant rise in revenue from pharma research and development services, which increased by 68.1% year-over-year.
The company’s gross profit also saw a notable increase of 13.3% from the previous year, reaching RMB108.1 million. This improvement was attributed to enhanced cost optimization measures and a shift towards higher-margin projects. Operating expenses were significantly reduced by 42.1%, primarily due to budget control measures and a reduction in headcount.
Despite these positive developments, Burning Rock reported a net loss of RMB9.7 million for the quarter, a substantial improvement from the RMB108.0 million loss recorded in the same period last year. The company’s cash reserves stood at RMB455.0 million as of June 30, 2025.
Looking ahead, Burning Rock remains focused on its strategic transition towards in-hospital testing and continues to optimize its operations. The management is committed to leveraging its expertise in precision oncology to drive future growth and improve financial performance.